The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|June 21, 2010
We've raised the bar!
Now Agilent has raised the HPLC standard.
Advertisement
Agilent 1290 Infinity LC ended the UHPLC debate. Now Agilent has raised the HPLC standard. The new 1220 and 1260 Infinity LC give you RRLC capabilities at an HPLC price: 600 bar and 80 Hz detector speed. All systems are up to 10x more sensitive and 100% compatible with all your HPLC methods.
Together this new portfolio offers a unique continuum of future-proof HPLC, RRLC, and UHPLC solutions to ensure riskless replacement of existing instruments. All to match any application or budget. And all from a name you trust for the highest quality Agilent.
Learn why the 1200 Infinity Series is infinitely better and configure your best-price system online at:
Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement